Immunotherapy With the Highly Activated NK Cells for AIDS Patients of Good Viral Suppression But Poor Immune Rebuilding

Trial Profile

Immunotherapy With the Highly Activated NK Cells for AIDS Patients of Good Viral Suppression But Poor Immune Rebuilding

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Natural killer cell therapy Shenzhen Hank Bioengineering Institute (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top